非筋肉浸潤性膀胱癌の治療薬に関する市場調査：化学療法剤がトップシェアを占める

Market Study on Non-muscle Invasive Bladder Cancer Therapeutics: Chemotherapy Drugs Account for Leading Market Share

非筋肉浸潤性膀胱癌治療薬市場：レポートスコープ Persistence Market Research社の調査レポート「世界の非筋肉浸潤性膀胱癌治療薬市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応するセクシ... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Persistence Market Research パーシスタンスマーケットリサーチ	2023年4月28日	US$4,900 シングルユーザライセンスライセンス・価格情報注文方法はこちら	345	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

非筋肉浸潤性膀胱癌治療薬市場：レポートスコープ

Persistence Market Research社の調査レポート「世界の非筋肉浸潤性膀胱癌治療薬市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応するセクションについての詳細な分析、および最新情報を提供します。この調査レポートは、市場の促進要因、阻害要因、動向、機会を含む現在の市場力学に関する詳細な洞察を提供しています。この市場調査の主な目的は、2023年から2033年の予測期間中に市場がどのように推移するかについての独占情報を提示することです。

市場の成功的な成長のための重要な指標は、市場の前年比（YoY）成長分析、複合年間成長率（CAGR）を含むこの包括的なレポートで提示され、Persistence Market Research社の調査で網羅的に説明されています。この調査研究は、非筋肉浸潤性膀胱癌治療薬の需要と調査期間中の定量的な開発機会を知るために読者をサポートすることができます。

この調査は、投資家、メーカー、サービスプロバイダー、流通業者、サプライヤーなどの景観の株主にとって有益であり、非筋肉浸潤性膀胱癌治療薬市場で繁栄するための適切なビジネス戦略の開発に役立てることができます。非筋肉浸潤性膀胱癌治療薬市場の株主、業界専門家、投資家、研究者、記者、ビジネス愛好家は、このPersistence Market Researchの調査で示された洞察と情報を活用できます。

市場統計、および非筋肉浸潤性膀胱癌治療薬市場のビジネスシナリオに影響を与えるマクロ経済変数と同様にマクロ経済変数に関連する情報も、現在の研究に含まれています。市場の潜在的な発展に応じて、実質的な洞察も本レポートで遭遇することができます。さらに、本レポートで提出されたデータによって、業界のマイナーな企業や新規参入者は、市場で牽引力を発揮するために適切な企業選択をする際に支援されることができます。

主要な市場セグメント

Persistence Market Research社の非筋肉浸潤性膀胱癌治療薬市場に関する調査レポートは、癌のグレード、薬剤タイプ、流通チャネル、地域の4つの重要なセグメントに分けて情報を提供しています。本レポートでは、これらのカテゴリーに関連する重要な市場力学と成長パラメータに関する包括的なデータと情報を提供します。

癌のグレード
低悪性度膀胱がん
高悪性度膀胱がん
薬剤の種類
免疫療法
カルメット・ゲリン菌
アベルマブ
ニボルマブ
ペムブロリズマブ
その他
化学療法
マイトマイシンC
ドセタキセル
パクリタキセル
シスプラチン
その他
標的治療薬
エルダフィチニブ
エンフォルマブ・ベドチン-ejfv
サシツズマブゴビテカン
その他
販売チャネル
病院薬局
小売薬局
スペシャリティファーマシー
オンライン薬局
地域別
北アメリカ
中南米
ヨーロッパ
南アジア
東アジア
オセアニア
中東・アフリカ(MEA)
報告書に記載されている主な質問

今後数年間、非筋肉浸潤性膀胱がん治療薬の最も収益性の高い市場であり続けるのはどの地域か？
トレンドの変化は市場にどのような影響を与えるのか？
COVID-19危機は市場成長にどのような影響を与えたか？
市場関係者はどのようにして先進国の低空飛行の機会を捉えることができるのか？
市場関係者は、このランドスケープにおける自らのポジションを形成するために、どのような戦略を持っているのか？
投資家が市場に投資する際に認識する必要があり、取り組む可能性のある抑制要因とは？
市場に影響を与える発展的なトレンドは何か？
非筋肉浸潤性膀胱がん治療薬市場の企業は、先進国および新興国での成長機会をどのように利用できるのか？
調査方法

Persistence Market Research社の調査レポートでは、非筋肉浸潤性膀胱癌治療薬市場の成長に関する広範な調査を実施し、市場の将来の成長パラメータに関する結論を得るために、独自の調査手法を利用しています。この調査手法は、一次調査と二次調査を組み合わせたもので、アナリストが結論の正確性と信頼性を確保するのに役立ちます。

市場調査作成時にアナリストが参照した二次資料には、政府機関の統計、業界誌、白書、社内外の独自データベースなどがあります。アナリストは、一次資料として、本レポートの作成に貢献したシニアマネージャー、製品ポートフォリオマネージャー、CEO、副社長、マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャーにインタビューを行った。

一次および二次リソースから取得した包括的な情報は、市場の企業からの検証として機能し、非筋肉浸潤性膀胱癌治療薬市場の成長見通しに関するPersistence Market Researchの予測はより正確で信頼できるものとなっています。

ページTOPに戻る

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trend

1.3. Supply Side Trend

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Innovation/Development Trends

4. Value Added Insights

4.1. Cancer Grade Adoption Analysis

4.2. Key Strategies, by Manufacturers

4.3. Regulatory Scenario

4.4. PESTLE Analysis

4.5. Porter’s Analysis

4.6. Supply Chain Analysis

4.7. Funding In Research and Development

4.8. Clinical Trails Analysis

4.9. Pipeline Analysis

4.10. Disease Epidemiology, by region

4.11. Reimbursement Scenario

5. Market Background

5.1. Macro-Economic Factors

5.1.1. Global GDP Growth Outlook

5.1.2. Global Pharmaceutical Industry Outlook

5.1.3. Global Bladder Cancer Therapeutics Market Overview

5.2. Forecast Factors - Relevance & Impact

5.2.1. Rising Healthcare Spending

5.2.2. Increasing Prevalence of Cancer

5.2.3. Increase Awareness and Supportive Government Initiatives

5.2.4. Increase in Funding

5.2.5. Cancer Research

5.2.6. Increase In Cancer Grade Launches

5.2.7. Strong Cancer Grade Pipelines

5.3. Market Dynamics

5.3.1. Drivers

5.3.2. Restraints

5.3.3. Opportunity

6. COVID-19 Crisis – Impact Assessment

6.1. COVID-19 and Impact Analysis

6.1.1. By Cancer Grade

6.1.2. By Drug type

6.1.3. By Distribution Channel

6.1.4. By Region

6.2. 2022 Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012–2022 and Forecast, 2023–2033

7.1. Historical Market Value (US$ Mn) Analysis, 2012–2022

7.2. Current and Future Market Value (US$ Mn) Projections, 2023–2033

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Cancer Grade

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Cancer Grade, 2012–2022

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Cancer Grade, 2023–2033

8.3.1. Low Grade Bladder Cancer

8.3.2. High Grade Bladder Cancer

8.4. Market Attractiveness Analysis By Cancer Grade

9. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Drug type

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) By Drug type, 2012–2022

9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug type, 2023–2033

9.3.1. Immunotherapy

9.3.1.1. Bacillus Calmette-Guerin

9.3.1.2. Avelumab

9.3.1.3. Nivolumab

9.3.1.4. Pembrolizumab

9.3.1.5. Others

9.3.2. Chemotherapy

9.3.2.1. Mitomycin C

9.3.2.2. Docetaxel

9.3.2.3. Paclitaxel

9.3.2.4. Cisplatin

9.3.2.5. Others

9.3.3. Targeted therapy

9.3.3.1. Erdafitinib

9.3.3.2. Enfortumab vedotin-ejfv

9.3.3.3. Sacituzumab govitecan

9.3.3.4. others

9.4. Market Attractiveness Analysis By Drug type

10. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Distribution Channel

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) By Distribution Channel, 2012–2022

10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023–2033

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Specialty Pharmacies

10.3.4. Online Pharmacies

10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Region

11.1. Introduction

11.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2022

11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023–2033

11.3.1. North America

11.3.2. Latin America

11.3.3. Europe

11.3.4. East Asia

11.3.5. South Asia

11.3.6. Oceania

11.3.7. Middle East and Africa (MEA)

11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2012–2022 and Forecast 2023–2033

12.1. Introduction

12.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2012–2022

12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023–2033

12.3.1. By Country

12.3.1.1. U.S.

12.3.1.2. Canada

12.3.2. By Cancer Grade

12.3.3. By Drug type

12.3.4. By Distribution Channel

12.4. Market Attractiveness Analysis

12.4.1. By Country

12.4.2. By Cancer Grade

12.4.3. By Drug type

12.4.4. By Distribution Channel

12.5. Market Trends

12.6. Key Market Participants - Intensity Mapping

12.7. Drivers and Restraints - Impact Analysis

12.8. Country Level Analysis & Forecast

12.8.1. U.S. Market Analysis

12.8.1.1. Introduction

12.8.1.2. Market Analysis and Forecast by Market Taxonomy

12.8.1.2.1. By Cancer Grade

12.8.1.2.2. By Drug type

12.8.1.2.3. By Distribution Channel

12.8.2. Canada Market Analysis

12.8.2.1. Introduction

12.8.2.2. Market Analysis and Forecast by Market Taxonomy

12.8.2.2.1. By Cancer Grade

12.8.2.2.2. By Drug type

12.8.2.2.3. By Distribution Channel

13. Latin America Market Analysis 2012–2022 and Forecast 2023–2033

13.1. Introduction

13.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2012–2022

13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023–2033

13.3.1. By Country

13.3.1.1. Mexico

13.3.1.2. Brazil

13.3.1.3. Argentina

13.3.1.4. Rest of Latin America

13.3.2. By Cancer Grade

13.3.3. By Drug type

13.3.4. By Distribution Channel

13.4. Market Attractiveness Analysis

13.4.1. By Country

13.4.2. By Cancer Grade

13.4.3. By Drug type

13.4.4. By Distribution Channel

13.5. Market Trends

13.6. Key Market Participants - Intensity Mapping

13.7. Drivers and Restraints - Impact Analysis

13.8. Country Level Analysis & Forecast

13.8.1. Mexico Market Analysis

13.8.1.1. Introduction

13.8.1.2. Market Analysis and Forecast by Market Taxonomy

13.8.1.2.1. By Cancer Grade

13.8.1.2.2. By Drug type

13.8.1.2.3. By Distribution Channel

13.8.2. Brazil Market Analysis

13.8.2.1. Introduction

13.8.2.2. Market Analysis and Forecast by Market Taxonomy

13.8.2.2.1. By Cancer Grade

13.8.2.2.2. By Drug type

13.8.2.2.3. By Distribution Channel

13.8.3. Argentina Market Analysis

13.8.3.1. Introduction

13.8.3.2. Market Analysis and Forecast by Market Taxonomy

13.8.3.2.1. By Cancer Grade

13.8.3.2.2. By Drug type

13.8.3.2.3. By Distribution Channel

14. Europe Market Analysis 2012–2022 and Forecast 2023–2033

14.1. Introduction

14.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2012–2022

14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023–2033

14.3.1. By Country

14.3.1.1. UK

14.3.1.2. Germany

14.3.1.3. France

14.3.1.4. Italy

14.3.1.5. Spain

14.3.1.6. BENELUX

14.3.1.7. Russia

14.3.1.8. Rest of Europe

14.3.2. By Cancer Grade

14.3.3. By Drug type

14.3.4. By Distribution Channel

14.4. Market Attractiveness Analysis

14.4.1. By Country

14.4.2. By Cancer Grade

14.4.3. By Drug type

14.4.4. By Distribution Channel

14.5. Market Trends

14.6. Key Market Participants - Intensity Mapping

14.7. Drivers and Restraints - Impact Analysis

14.8. Country Level Analysis & Forecast

14.8.1. U.K. Market Analysis

14.8.1.1. Introduction

14.8.1.2. Market Analysis and Forecast by Market Taxonomy

14.8.1.2.1. By Cancer Grade

14.8.1.2.2. By Drug type

14.8.1.2.3. By Distribution Channel

14.8.2. Germany Market Analysis

14.8.2.1. Introduction

14.8.2.2. Market Analysis and Forecast by Market Taxonomy

14.8.2.2.1. By Cancer Grade

14.8.2.2.2. By Drug type

14.8.2.2.3. By Distribution Channel

14.8.3. France Market Analysis

14.8.3.1. Introduction

14.8.3.2. Market Analysis and Forecast by Market Taxonomy

14.8.3.2.1. By Cancer Grade

14.8.3.2.2. By Drug type

14.8.3.2.3. By Distribution Channel

14.8.4. Italy Market Analysis

14.8.4.1. Introduction

14.8.4.2. Market Analysis and Forecast by Market Taxonomy

14.8.4.2.1. By Cancer Grade

14.8.4.2.2. By Drug type

14.8.4.2.3. By Distribution Channel

14.8.5. Spain Market Analysis

14.8.5.1. Introduction

14.8.5.2. Market Analysis and Forecast by Market Taxonomy

14.8.5.2.1. By Cancer Grade

14.8.5.2.2. By Drug type

14.8.5.2.3. By Distribution Channel

14.8.6. BENELUX Market Analysis

14.8.6.1. Introduction

14.8.6.2. Market Analysis and Forecast by Market Taxonomy

14.8.6.2.1. By Cancer Grade

14.8.6.2.2. By Drug type

14.8.6.2.3. By Distribution Channel

14.8.7. Russia Market Analysis

14.8.7.1. Introduction

14.8.7.2. Market Analysis and Forecast by Market Taxonomy

14.8.7.2.1. By Cancer Grade

14.8.7.2.2. By Drug type

14.8.7.2.3. By Distribution Channel

15. East Asia Market Analysis 2012–2022 and Forecast 2023–2033

15.1. Introduction

15.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2012–2022

15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023–2033

15.3.1. By Country

15.3.1.1. China

15.3.1.2. Japan

15.3.1.3. South Korea

15.3.2. By Cancer Grade

15.3.3. By Drug type

15.3.4. By Distribution Channel

15.4. Market Attractiveness Analysis

15.4.1. By Country

15.4.2. By Cancer Grade

15.4.3. By Drug type

15.4.4. By Distribution Channel

15.5. Market Trends

15.6. Key Market Participants - Intensity Mapping

15.7. Drivers and Restraints - Impact Analysis

15.8. Country Level Analysis & Forecast

15.8.1. China Market Analysis

15.8.1.1. Introduction

15.8.1.2. Market Analysis and Forecast by Market Taxonomy

15.8.1.2.1. By Cancer Grade

15.8.1.2.2. By Drug type

15.8.1.2.3. By Distribution Channel

15.8.2. Japan Market Analysis

15.8.2.1. Introduction

15.8.2.2. Market Analysis and Forecast by Market Taxonomy

15.8.2.2.1. By Cancer Grade

15.8.2.2.2. By Drug type

15.8.2.2.3. By Distribution Channel

15.8.3. South Korea Market Analysis

15.8.3.1. Introduction

15.8.3.2. Market Analysis and Forecast by Market Taxonomy

15.8.3.2.1. By Cancer Grade

15.8.3.2.2. By Drug type

15.8.3.2.3. By Distribution Channel

16. South Asia Market Analysis 2012–2022 and Forecast 2023–2033

16.1. Introduction

16.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2012–2022

16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023–2033

16.3.1. By Country

16.3.1.1. India

16.3.1.2. Malaysia

16.3.1.3. Thailand

16.3.1.4. Indonesia

16.3.1.5. Rest of South Asia

16.3.2. By Cancer Grade

16.3.3. By Drug type

16.3.4. By Distribution Channel

16.4. Market Attractiveness Analysis

16.4.1. By Country

16.4.2. By Cancer Grade

16.4.3. By Drug type

16.4.4. By Distribution Channel

16.5. Market Trends

16.6. Key Market Participants - Intensity Mapping

16.7. Drivers and Restraints - Impact Analysis

16.8. Country Level Analysis & Forecast

16.8.1. India Market Analysis

16.8.1.1. Introduction

16.8.1.2. Market Analysis and Forecast by Market Taxonomy

16.8.1.2.1. By Cancer Grade

16.8.1.2.2. By Drug type

16.8.1.2.3. By Distribution Channel

16.8.2. Malaysia Market Analysis

16.8.2.1. Introduction

16.8.2.2. Market Analysis and Forecast by Market Taxonomy

16.8.2.2.1. By Cancer Grade

16.8.2.2.2. By Drug type

16.8.2.2.3. By Distribution Channel

16.8.3. Thailand Market Analysis

16.8.3.1. Introduction

16.8.3.2. Market Analysis and Forecast by Market Taxonomy

16.8.3.2.1. By Cancer Grade

16.8.3.2.2. By Drug type

16.8.3.2.3. By Distribution Channel

16.8.4. Indonesia Market Analysis

16.8.4.1. Introduction

16.8.4.2. Market Analysis and Forecast by Market Taxonomy

16.8.4.2.1. By Cancer Grade

16.8.4.2.2. By Drug type

16.8.4.2.3. By Distribution Channel

17. Oceania Market Analysis 2012–2022 and Forecast 2023–2033

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2012–2022

17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023–2033

17.3.1. By Country

17.3.1.1. Australia

17.3.1.2. New Zealand

17.3.2. By Cancer Grade

17.3.3. By Drug type

17.3.4. By Distribution Channel

17.4. Market Attractiveness Analysis

17.4.1. By Country

17.4.2. By Cancer Grade

17.4.3. By Drug type

17.4.4. By Distribution Channel

17.5. Market Trends

17.6. Key Market Participants - Intensity Mapping

17.7. Drivers and Restraints - Impact Analysis

17.8. Country Level Analysis & Forecast

17.8.1. Australia Market Analysis

17.8.1.1. Introduction

17.8.1.2. Market Analysis and Forecast by Market Taxonomy

17.8.1.2.1. By Cancer Grade

17.8.1.2.2. By Drug type

17.8.1.2.3. By Distribution Channel

17.8.2. New Zealand Market Analysis

17.8.2.1. Introduction

17.8.2.2. Market Analysis and Forecast by Market Taxonomy

17.8.2.2.1. By Cancer Grade

17.8.2.2.2. By Drug type

17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Market Analysis 2012–2022 and Forecast 2023–2033

18.1. Introduction

18.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2012–2022

18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023–2033

18.3.1. By Country

18.3.1.1. GCC Countries

18.3.1.2. Türkiye

18.3.1.3. South Africa

18.3.1.4. Rest of Middle East and Africa

18.3.2. By Cancer Grade

18.3.3. By Drug type

18.3.4. By Distribution Channel

18.4. Market Attractiveness Analysis

18.4.1. By Country

18.4.2. By Cancer Grade

18.4.3. By Drug type

18.4.4. By Distribution Channel

18.5. Market Trends

18.6. Key Market Participants - Intensity Mapping

18.7. Drivers and Restraints - Impact Analysis

18.8. Country Level Analysis & Forecast

18.8.1. GCC Countries Market Analysis

18.8.1.1. Introduction

18.8.1.2. Market Analysis and Forecast by Market Taxonomy

18.8.1.2.1. By Cancer Grade

18.8.1.2.2. By Drug type

18.8.1.2.3. By Distribution Channel

18.8.2. Türkiye Market Analysis

18.8.2.1. Introduction

18.8.2.2. Market Analysis and Forecast by Market Taxonomy

18.8.2.2.1. By Cancer Grade

18.8.2.2.2. By Drug type

18.8.2.2.3. By Distribution Channel

18.8.3. South Africa Market Analysis

18.8.3.1. Introduction

18.8.3.2. Market Analysis and Forecast by Market Taxonomy

18.8.3.2.1. By Cancer Grade

18.8.3.2.2. By Drug type

18.8.3.2.3. By Distribution Channel

19. Market Structure Analysis

19.1. Market Analysis by Tier of Companies

19.2. Market Share Analysis of Top Players (%)

19.3. Market Presence Analysis

19.3.1. By Regional Footprint of Players

19.3.2. Product Footprint of Players

19.3.3. Channel Footprint of Players

20. Competition Analysis

20.1. Competition Dashboard

20.2. Competition Benchmarking

20.3. Competition Deep Dive

20.3.1. Pfizer Inc.

20.3.1.1. Overview

20.3.1.2. Product Portfolio

20.3.1.3. Key Financials

20.3.1.4. SWOT Analysis

20.3.1.5. Key Developments

20.3.1.6. Sales Footprint

20.3.1.7. Strategy Overview

20.3.1.7.1. Marketing Strategy

20.3.1.7.2. Product Strategy

20.3.1.7.3. Channel Strategy

20.3.2. Merck KGaA

20.3.2.1. Overview

20.3.2.2. Product Portfolio

20.3.2.3. Key Financials

20.3.2.4. SWOT Analysis

20.3.2.5. Key Developments

20.3.2.6. Sales Footprint

20.3.2.7. Strategy Overview

20.3.2.7.1. Marketing Strategy

20.3.2.7.2. Product Strategy

20.3.2.7.3. Channel Strategy

20.3.3. AstraZeneca PLC

20.3.3.1. Overview

20.3.3.2. Product Portfolio

20.3.3.3. Key Financials

20.3.3.4. SWOT Analysis

20.3.3.5. Key Developments

20.3.3.6. Sales Footprint

20.3.3.7. Strategy Overview

20.3.3.7.1. Marketing Strategy

20.3.3.7.2. Product Strategy

20.3.3.7.3. Channel Strategy

20.3.4. Roche Holding AG (Genentech)

20.3.4.1. Overview

20.3.4.2. Product Portfolio

20.3.4.3. Key Financials

20.3.4.4. SWOT Analysis

20.3.4.5. Key Developments

20.3.4.6. Sales Footprint

20.3.4.7. Strategy Overview

20.3.4.7.1. Marketing Strategy

20.3.4.7.2. Product Strategy

20.3.4.7.3. Channel Strategy

20.3.5. Astellas Pharma Inc.

20.3.5.1. Overview

20.3.5.2. Product Portfolio

20.3.5.3. Key Financials

20.3.5.4. SWOT Analysis

20.3.5.5. Key Developments

20.3.5.6. Sales Footprint

20.3.5.7. Strategy Overview

20.3.5.7.1. Marketing Strategy

20.3.5.7.2. Product Strategy

20.3.5.7.3. Channel Strategy

20.3.6. J&J (Janssen Biotech)

20.3.6.1. Overview

20.3.6.2. Product Portfolio

20.3.6.3. Key Financials

20.3.6.4. SWOT Analysis

20.3.6.5. Key Developments

20.3.6.6. Sales Footprint

20.3.6.7. Strategy Overview

20.3.6.7.1. Marketing Strategy

20.3.6.7.2. Product Strategy

20.3.6.7.3. Channel Strategy

20.3.7. Cipla Inc.

20.3.7.1. Overview

20.3.7.2. Product Portfolio

20.3.7.3. Key Financials

20.3.7.4. SWOT Analysis

20.3.7.5. Key Developments

20.3.7.6. Sales Footprint

20.3.7.7. Strategy Overview

20.3.7.7.1. Marketing Strategy

20.3.7.7.2. Product Strategy

20.3.7.7.3. Channel Strategy

20.3.8. Amneal Pharma

20.3.8.1. Overview

20.3.8.2. Product Portfolio

20.3.8.3. Key Financials

20.3.8.4. SWOT Analysis

20.3.8.5. Key Developments

20.3.8.6. Sales Footprint

20.3.8.7. Strategy Overview

20.3.8.7.1. Marketing Strategy

20.3.8.7.2. Product Strategy

20.3.8.7.3. Channel Strategy

20.3.9. Bristol Myers Squibb Co.

20.3.9.1. Overview

20.3.9.2. Product Portfolio

20.3.9.3. Key Financials

20.3.9.4. SWOT Analysis

20.3.9.5. Key Developments

20.3.9.6. Sales Footprint

20.3.9.7. Strategy Overview

20.3.9.7.1. Marketing Strategy

20.3.9.7.2. Product Strategy

20.3.9.7.3. Channel Strategy

20.3.10. Dr. Reddy’s Laboratories, Inc.

20.3.10.1. Overview

20.3.10.2. Product Portfolio

20.3.10.3. Key Financials

20.3.10.4. SWOT Analysis

20.3.10.5. Key Developments

20.3.10.6. Sales Footprint

20.3.10.7. Strategy Overview

20.3.10.7.1. Marketing Strategy

20.3.10.7.2. Product Strategy

20.3.10.7.3. Channel Strategy

20.3.11. Gilead Sciences Inc.

20.3.11.1. Overview

20.3.11.2. Product Portfolio

20.3.11.3. Key Financials

20.3.11.4. SWOT Analysis

20.3.11.5. Key Developments

20.3.11.6. Sales Footprint

20.3.11.7. Strategy Overview

20.3.11.7.1. Marketing Strategy

20.3.11.7.2. Product Strategy

20.3.11.7.3. Channel Strategy

20.3.12. Endo Pharma

20.3.12.1. Overview

20.3.12.2. Product Portfolio

20.3.12.3. Key Financials

20.3.12.4. SWOT Analysis

20.3.12.5. Key Developments

20.3.12.6. Sales Footprint

20.3.12.7. Strategy Overview

20.3.12.7.1. Marketing Strategy

20.3.12.7.2. Product Strategy

20.3.12.7.3. Channel Strategy

20.3.13. UroGen Pharma, Inc.

20.3.13.1. Overview

20.3.13.2. Product Portfolio

20.3.13.3. Key Financials

20.3.13.4. SWOT Analysis

20.3.13.5. Key Developments

20.3.13.6. Sales Footprint

20.3.13.7. Strategy Overview

20.3.13.7.1. Marketing Strategy

20.3.13.7.2. Product Strategy

20.3.13.7.3. Channel Strategy

20.3.14. Teva Pharmaceuticals (Actavis)

20.3.14.1. Overview

20.3.14.2. Product Portfolio

20.3.14.3. Key Financials

20.3.14.4. SWOT Analysis

20.3.14.5. Key Developments

20.3.14.6. Sales Footprint

20.3.14.7. Strategy Overview

20.3.14.7.1. Marketing Strategy

20.3.14.7.2. Product Strategy

20.3.14.7.3. Channel Strategy

20.3.15. Hikma Pharmaceuticals

20.3.15.1. Overview

20.3.15.2. Product Portfolio

20.3.15.3. Key Financials

20.3.15.4. SWOT Analysis

20.3.15.5. Key Developments

20.3.15.6. Sales Footprint

20.3.15.7. Strategy Overview

20.3.15.7.1. Marketing Strategy

20.3.15.7.2. Product Strategy

20.3.15.7.3. Channel Strategy

20.3.16. Incyte

20.3.16.1. Overview

20.3.16.2. Product Portfolio

20.3.16.3. Key Financials

20.3.16.4. SWOT Analysis

20.3.16.5. Key Developments

20.3.16.6. Sales Footprint

20.3.16.7. Strategy Overview

20.3.16.7.1. Marketing Strategy

20.3.16.7.2. Product Strategy

20.3.16.7.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

ページTOPに戻る

Table of Contents

Summary

Non-muscle Invasive Bladder Cancer Therapeutics Market: Report Scope

The latest publication by Persistence Market Research on the global non-muscle invasive bladder cancer therapeutics market evaluates the opportunities and current market landscape and provides detailed analysis, and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023 to 2033.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for non-muscle invasive bladder cancer therapeutic drugs and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the non-muscle invasive bladder cancer therapeutics market. Shareholders in the non-muscle invasive bladder cancer therapeutics market, industry experts, investors, researchers, and reporters, as well as business enthusiasts, can leverage insights and information presented in this Persistence Market Research study.

Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the non-muscle invasive bladder cancer therapeutics market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the non-muscle invasive bladder cancer therapeutics market offers information divided into four important segments - cancer grade, drug type, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Cancer Grade
Low-grade Bladder Cancer
High-grade Bladder Cancer
Drug Type
Immunotherapy
Bacillus Calmette-Guerin
Avelumab
Nivolumab
Pembrolizumab
Others
Chemotherapy
Mitomycin C
Docetaxel
Paclitaxel
Cisplatin
Others
Targeted therapy
Erdafitinib
Enfortumab Vedotin-ejfv
Sacituzumab Govitecan
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)
Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for non-muscle invasive bladder cancer therapeutics over the coming years?
How will changing trends influence the market?
How has the COVID-19 crisis influenced market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will influence the market?
How can companies in the non-muscle invasive bladder cancer therapeutics market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the non-muscle invasive bladder cancer therapeutics market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the non-muscle invasive bladder cancer therapeutics market are more accurate and reliable.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

Persistence Market Research社の医療・製薬・メディカルデバイス分野での最新刊レポート

本レポートと同じKEY WORD（bladder cancer）の最新刊レポート

よくあるご質問

Persistence Market Research社はどのような調査会社ですか?

パーシスタンスマーケットリサーチ（Persistence Market Research/PMR）は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

非筋肉浸潤性膀胱癌の治療薬に関する市場調査：化学療法剤がトップシェアを占める

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

Persistence Market Research社の医療・製薬・メディカルデバイス分野での最新刊レポート

本レポートと同じKEY WORD（bladder cancer）の最新刊レポート

よくあるご質問

Persistence Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?